Top Page
Sinopharm Group Co
(OTC:1099)
Sinopharm Group Co (1099) vs. iShares MSCI Hong Kong ETF (EWH)
Sinopharm Group Co Business Overview & Revenue Model
Sinopharm Group Co Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 584.51B | 596.57B | 552.15B | 521.05B | 456.41B |
| Gross Profit | 44.26B | 48.51B | 47.43B | 44.05B | 40.32B |
| EBITDA | 20.17B | 26.90B | 26.25B | 24.68B | 22.62B |
| Net Income | 7.05B | 9.05B | 14.35B | 13.06B | 12.10B |
Balance Sheet | |||||
| Total Assets | 392.83B | 383.39B | 364.78B | 335.41B | 311.24B |
| Cash, Cash Equivalents and Short-Term Investments | 54.31B | 63.81B | 55.22B | 43.54B | 50.22B |
| Total Debt | 76.39B | 73.78B | 69.59B | 68.37B | 68.53B |
| Total Liabilities | 266.14B | 263.08B | 254.71B | 235.76B | 221.29B |
| Stockholders Equity | 78.88B | 74.58B | 68.07B | 61.89B | 56.36B |
Cash Flow | |||||
| Free Cash Flow | 9.58B | 14.84B | 18.55B | 7.05B | 9.07B |
| Operating Cash Flow | 11.55B | 17.17B | 20.96B | 9.31B | 11.15B |
| Investing Cash Flow | -3.75B | -944.53M | -3.59B | -1.27B | -2.20B |
| Financing Cash Flow | -17.29B | -7.64B | -5.69B | -14.69B | 2.03B |
Sinopharm Group Co Technical Analysis
Sinopharm Group Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $57.32B | 7.50 | 9.19% | 4.02% | -3.94% | -23.48% | |
51 Neutral | $7.55B | 0.30 | -61.90% | 2.27% | 17.11% | 1.58% | |
| $8.32B | 9.16 | 6.08% | 3.02% | ― | ― | ||
78 Outperform | HK$3.57B | 11.65 | 7.40% | 4.17% | 0.67% | -1.75% | |
| HK$761.40M | 13.18 | 8.78% | 6.93% | ― | ― |
Sinopharm Group Co Corporate Events
Sinopharm Group Co. Ltd. announced the successful conclusion of its 2024 annual general meeting and related shareholder meetings held on June 12, 2025. All proposed resolutions, including the approval of the company’s financial statements, profit distribution plan, and final dividend for 2024, were passed with significant majority votes. This outcome reflects strong shareholder support and positions the company favorably for continued growth and stability in the pharmaceutical sector.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
Sinopharm Group Co. Ltd. has announced the composition of its board of directors and the roles and functions of each member. The board includes non-executive, executive, and independent non-executive directors, with Zhao Bingxiang serving as the Chairman. The announcement also details the membership of five board committees, highlighting the company’s commitment to governance and strategic oversight.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
Sinopharm Group Co. Ltd. has announced an update to its final dividend distribution for the financial year ending December 31, 2024. The dividend is set at RMB 0.68 per share, equivalent to HKD 0.739 per share, with an exchange rate of RMB 1 to HKD 1.087. The ex-dividend date is June 16, 2025, and the payment date is August 12, 2025. The announcement includes details on withholding tax rates for non-resident enterprise and individual shareholders, as well as for Mainland individual investors through the Shanghai and Shenzhen Hong Kong Stock Connect. This update reflects Sinopharm’s commitment to shareholder returns and may influence investor sentiment and market positioning.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
Sinopharm Group Co. Ltd. announced the resignation of Mr. Liu Hongbing as an employee representative supervisor, effective from June 10, 2025. The company expressed gratitude for his contributions, and Mr. Liu confirmed no disagreements with the board, indicating a smooth transition without impact on stakeholders.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
Sinopharm Group Co. Ltd. announced the resignation of Mr. Hu Ligang from his position as a non-executive director, effective immediately, with his subsequent appointment as vice president of the company. The board expressed gratitude for Mr. Hu’s contributions to the company’s strategic development. Simultaneously, the board proposed the appointment of Mr. Ma Yue as a non-executive director, pending shareholder approval. Mr. Ma, a senior economist and practicing pharmacist, brings extensive experience from his tenure at China National Pharmaceutical Group Co., Ltd.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
Sinopharm Group Co. Ltd. has announced the composition of its board of directors, detailing the roles and functions of each member. The announcement outlines the structure of five board committees, highlighting the leadership and membership roles of the directors, which may impact the company’s governance and strategic direction.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
Sinopharm Group Co. Ltd. has announced its annual general meeting for 2024, scheduled for June 12, 2025, in Shanghai, China. Key agenda items include the approval of financial statements, profit distribution, director and supervisor remuneration, auditor appointments, and the delegation of guarantee provisions for subsidiaries. The meeting will also consider the appointment of new directors and the issuance of new shares, reflecting the company’s strategic focus on strengthening its governance and financial structure.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
Sinopharm Group Co. Ltd. has announced a special resolution for a shareholders’ class meeting to grant the Board a mandate to repurchase up to 10% of its H Shares. This move is aimed at enhancing capital management flexibility and potentially stabilizing the company’s share price, reflecting a strategic decision to optimize shareholder value.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
Sinopharm Group Co. Ltd. has announced a domestic shareholders’ class meeting to discuss a special resolution granting the Board a mandate to repurchase up to 10% of its H Shares. This move is aimed at enhancing capital management flexibility and potentially improving shareholder value, reflecting the company’s strategic focus on optimizing its capital structure.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
Sinopharm Group Co. Ltd. announced the composition of its board of directors, detailing the roles and functions of each member. The announcement highlights the company’s governance structure, with a focus on the various board committees and their respective members. This update may impact the company’s strategic direction and governance, influencing stakeholders’ perceptions and the company’s industry positioning.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
Sinopharm Group Co. Ltd. announced the resignation of Mr. Li Dongjiu as a non-executive director due to retirement, effective immediately. The board expressed gratitude for his contributions to the company’s development and governance. Concurrently, the board proposed the appointment of Mr. Chen Yuqing as a new non-executive director, subject to shareholder approval. Mr. Chen, who holds significant experience in human resources and management positions at Fosun Pharma, is expected to enhance Sinopharm’s strategic direction and governance.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
Sinopharm Group Co. Ltd. announced the resignation of Mr. Chen Fangruo as an independent non-executive director due to the completion of his term. The company expressed gratitude for his contributions to its development and governance. Concurrently, the board proposed the appointment of Mr. Chen Weiru as a new independent non-executive director, pending shareholder approval. Mr. Chen Weiru brings extensive experience in strategy formulation and corporate management, which is expected to enhance the board’s diversity and strategic capabilities.
Sinopharm Group Co. Ltd. announced its unaudited financial results for the first quarter of 2025, revealing a total asset increase to RMB 415.08 billion from RMB 392.67 billion at the end of 2024. The financial disclosure, required by Hong Kong and Shanghai stock exchange regulations, highlights a significant rise in accounts receivables, indicating robust business operations and potential growth in the pharmaceutical distribution sector.
Sinopharm Group Co. Ltd. reported its unaudited financial results for the first quarter ending March 31, 2025. The company saw a 4.87% increase in revenue compared to the same period last year, reaching approximately RMB 12.71 billion. However, net profit attributable to shareholders slightly decreased by 0.10%. The net cash flow from operating activities was negative, indicating potential liquidity challenges. Despite these mixed results, the company’s total assets and equity attributable to shareholders showed modest growth, suggesting a stable financial position.
Sinopharm Group Co. Ltd. announced the unaudited financial results for its subsidiary, Sinopharm Accord, for the first quarter ended March 31, 2025. The company reported a decline in revenue by 4.17% and a 15.63% decrease in net profit attributable to shareholders compared to the same period last year. Additionally, there was a significant drop in net cash flow from operating activities by 186.57%. Despite these declines, the total assets increased by 5.19%, indicating a potential for long-term growth.
Sinopharm Group Co. Ltd. announced the principal unaudited financial data for its subsidiary, China National Medical Device Co., Ltd. (CNMDC), for the first quarter of 2025. The report highlights a slight decline in revenue by 0.94% and a 7.39% drop in operating profit compared to the same period last year. However, total comprehensive income attributable to the parent company’s owners increased by 5.79%. Notably, net cash flow from operating activities improved significantly, showing a 56.34% decrease in negative cash flow. These financial results indicate a stable asset growth with total assets increasing by 2.83% and total equity rising by 1.58%, reflecting a cautious yet positive outlook for the company’s financial health.
Sinopharm Group Co. Ltd. has announced a board meeting scheduled for April 25, 2025, to review and approve the unaudited quarterly results for the first quarter of 2025. This meeting is crucial for assessing the company’s financial performance and strategic direction, potentially impacting stakeholders’ perceptions and the company’s market positioning.
Sinopharm Accord reported a slight decrease in revenue for 2024, down 1.46% to RMB74.378 billion. The company’s net profit attributable to shareholders fell significantly by 59.83% to RMB642 million, indicating challenges in maintaining profitability despite a slight increase in net assets. The financial results reflect a substantial decline in operating and total profits, impacting the company’s return on equity and earnings per share.